81 related articles for article (PubMed ID: 28063100)
1. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
[TBL] [Abstract][Full Text] [Related]
2. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
Tanna AP; Johnson M
Ophthalmology; 2018 Nov; 125(11):1741-1756. PubMed ID: 30007591
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pressure-lowering effects of ripasudil on open-angle glaucoma in eyes with high myopia and pathological myopia.
Yoshida T; Yoshimoto S; Nomura T; Ito T; Ohno M; Yasuda S; Shiotani Y; Ohno-Matsui K
Sci Rep; 2023 Dec; 13(1):22888. PubMed ID: 38129467
[TBL] [Abstract][Full Text] [Related]
4. Switching to Brimonidine/Ripasudil Fixed Combination from Brimonidine + Ripasudil.
Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Tomita G; Ishida K
Clin Ophthalmol; 2024; 18():423-430. PubMed ID: 38343903
[TBL] [Abstract][Full Text] [Related]
5. Effect of a fixed combination of ripasudil and brimonidine on aqueous humor dynamics in mice.
Yamagishi-Kimura R; Honjo M; Aihara M
Sci Rep; 2024 Apr; 14(1):7861. PubMed ID: 38570526
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of the Rho-Kinase Inhibitor (Ripasudil) in Bleb Needling after Trabeculectomy: A Prospective Multicenter Study.
Mizuno Y; Komatsu K; Tokumo K; Okada N; Onoe H; Okumichi H; Hirooka K; Aoki G; Miura Y; Kiuchi Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202082
[TBL] [Abstract][Full Text] [Related]
7. Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis.
Yang M; Kamoi K; Zong Y; Zhang J; Zou Y; Ohno-Matsui K
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542203
[TBL] [Abstract][Full Text] [Related]
8. Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma.
Al-Humimat G; Marashdeh I; Daradkeh D; Kooner K
J Exp Pharmacol; 2021; 13():197-212. PubMed ID: 33664600
[TBL] [Abstract][Full Text] [Related]
9. Effects of Brimonidine, Omidenepag Isopropyl, and Ripasudil Ophthalmic Solutions to Protect against H
Liu M; Honjo M; Yamagishi R; Aihara M
Curr Eye Res; 2023 Nov; 48(11):1014-1025. PubMed ID: 37466387
[TBL] [Abstract][Full Text] [Related]
10. Reticular Epithelial Edema in a Postkeratoplasty Eye Due to Ripasudil.
Singh C; Chaurasia S
Asia Pac J Ophthalmol (Phila); 2023 Mar-Apr 01; 12(2):270. PubMed ID: 35342186
[No Abstract] [Full Text] [Related]
11. Axonal protection by combination of ripasudil and brimonidine with upregulation of p-AMPK in TNF-induced optic nerve degeneration.
Otsubo M; Sase K; Tsukahara C; Fujita N; Arizono I; Tokuda N; Kitaoka Y
Int Ophthalmol; 2024 Apr; 44(1):173. PubMed ID: 38598101
[TBL] [Abstract][Full Text] [Related]
12. ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs.
Pagano L; Lee JW; Posarelli M; Giannaccare G; Kaye S; Borgia A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959203
[TBL] [Abstract][Full Text] [Related]
13. [Ripasudil as Option for Medical Treatment of Corneal Endothelial Decompensation Secondary to Endotheliitis].
Filev FS; Chankiewitz E; Le T; Rockel M; von Jagow B
Klin Monbl Augenheilkd; 2024 May; 241(5):682-684. PubMed ID: 37567566
[No Abstract] [Full Text] [Related]
14. Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4.
Terao E; Nakakura S; Nagata Y; Dote S; Tabuchi H; Kiuchi Y
Cureus; 2020 Sep; 12(9):e10368. PubMed ID: 33062491
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study.
Matsumura R; Inoue T; Matsumura A; Tanihara H
Clin Drug Investig; 2017 Jun; 37(6):535-539. PubMed ID: 28349329
[TBL] [Abstract][Full Text] [Related]
16. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
[TBL] [Abstract][Full Text] [Related]
17. Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys.
Kaneko Y; Ohta M; Isobe T; Nakamura Y; Mizuno K
J Ophthalmol; 2017; 2017():7079645. PubMed ID: 28540083
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
19. A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.
Yamada H; Yoneda M; Inaguma S; Gosho M; Murasawa Y; Isogai Z; Zako M
J Ocul Pharmacol Ther; 2017 Apr; 33(3):176-185. PubMed ID: 28157424
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans.
Kazemi A; McLaren JW; Kopczynski CC; Heah TG; Novack GD; Sit AJ
J Ocul Pharmacol Ther; 2018 Jun; 34(5):380-386. PubMed ID: 29469601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
